



BRINGING EQUITY AND EFFICACY TOGETHER IN TRIPLE-NEGATIVE BREAST CANCER

A Practical Guide for
the Oncology Nurse



Presented by
Creative Educational Concepts, LLC.
Supported by an independent
educational grant from Gilead.



Jennifer McKenna, RN, MSN, AOCNP

Oncology Nurse Practitioner
Division of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:

Jennifer A. McKenna, NP—has no relevant financial relationships to disclose in relation to the content of this activity.

Bryan C. Taylor, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:

Jennifer A. McKenna, NP—has no relevant financial relationships to disclose in relation to the content of this activity.

Elahe Salehi, DNP, ANP-BC—has no relevant financial relationships to disclose in relation to the content of this activity.

Content Reviewer:

Lauren Olade, RN—has disclosed that she is on the speakers' bureau for Gilead.

Thank You

Presented by Creative Educational Concepts



Supported through an independent educational grant from Gilead

Learning Objectives

- Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies oncology nurses can employ to promote equitable care and outcomes for all patients.
- Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, with a particular focus on toxicity management, for oncology nurses who care for TNBC patients receiving ADCs.
- Examine completed, ongoing, and planned clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
- Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus, strategies for anticipating, recognizing, and treating adverse events, and effectively integrating socioeconomic and other non-biologic factors into equitable cancer care.

Accreditation

- Nurses: 1.0 ANCC contact hour:

<https://www.surveymonkey.com/r/TTWCZWM>

